Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAF-HCM
2025-523090-42-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Aficamten with Placebo (2 arms). Primary endpoint: Change in post-Valsalva left ventricular outflow tract gradient. Planned start Sep 2026; status: authorised.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2025-523090-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523090-42-00.